$21.88 +0.78 (%) Sarepta Therapeutics Inc - NASDAQ

Oct. 1, 2014 | 04:00 PM

Partner Headlines

  1. Benzinga's Volume Movers

    Benzinga | Oct. 1, 2014 | 10:18AM EST
  2. Morning Market Movers

    Benzinga | Oct. 1, 2014 | 09:39AM EST
  3. Benzinga's Top #PreMarket Gainers

    Benzinga | Oct. 1, 2014 | 08:06AM EST
  4. Making Money With Charles Payne: 09/30/14

    FoxBusiness | Oct. 1, 2014 | 06:18AM EST
  5. Sarepta Reports Favorable Safety Results from Phase I Study of AVI-7100

    Benzinga | Sep. 30, 2014 | 07:32AM EST
  6. Credit Suisse Bullish On Sarepta Therapeutics Inc

    Benzinga | Sep. 24, 2014 | 09:22AM EST
  7. Biotechs That Might Benefit From Ebola

    Benzinga | Aug. 11, 2014 | 15:29PM EST
  8. Tekmira Ebola Drug Hold Lifted By FDA, Stock Soars

    IBD | Aug. 8, 2014 | 14:04PM EST
  9. Benzinga's Top #PreMarket Gainers

    Benzinga | Aug. 5, 2014 | 08:19AM EST
  10. Stocks Mixed Despite Better-Than-Expected GDP

    Benzinga | Jul. 30, 2014 | 16:43PM EST
  11. Sarepta Up 12% As FDA Is 'Actively Engaged' On Drug Application

    Benzinga | Jul. 30, 2014 | 11:33AM EST
  12. Morning Market Losers

    Benzinga | Jul. 24, 2014 | 09:54AM EST
  13. Benzinga's Top #PreMarket Losers

    Benzinga | Jul. 24, 2014 | 08:16AM EST
  14. Shares of Sarepta Therapeutics Plummet on CSO Termination

    Benzinga | Jul. 24, 2014 | 07:42AM EST
  15. Mid-Afternoon Market Movers For July 10, 2014

    Benzinga | Jul. 10, 2014 | 15:42PM EST
  16. Deutsche Bank Questions Long-Term Efficacy Of Sarepta's Eteplirsen Following Trial News

    Benzinga | Jul. 10, 2014 | 15:24PM EST
  17. Lumber Liquidators Falls On Weak Forecast; Zumiez Shares Spike Higher

    Benzinga | Jul. 10, 2014 | 12:44PM EST
  18. Markets Open Lower; Family Dollar Profit Misses Estimates

    Benzinga | Jul. 10, 2014 | 10:40AM EST
  19. Morning Market Losers

    Benzinga | Jul. 10, 2014 | 09:51AM EST
  20. UPDATE: Sarepta Therapeutics Announces $100M Proposed Public Offering of Common Stock

    Benzinga | Apr. 22, 2014 | 16:44PM EST
  21. Five Star Stock Watch: Sarepta Therapeutics

    Benzinga | Apr. 22, 2014 | 12:54PM EST
  22. Benzinga's Top Upgrades

    Benzinga | Apr. 22, 2014 | 08:03AM EST
  23. Mid-Afternoon Market Update: Markets Remain in the Green as Moneygram Falls Further

    Benzinga | Apr. 21, 2014 | 15:26PM EST
  24. Sarepta Revives Hopes For Muscular Dystrophy Drug

    IBD | Apr. 21, 2014 | 13:13PM EST
  25. Mid-Day Market Update: AMD Surges After Upbeat Results; Acacia Research Shares Decline

    Benzinga | Apr. 21, 2014 | 12:42PM EST
  26. Benzinga's Volume Movers

    Benzinga | Apr. 21, 2014 | 11:00AM EST
  27. Mid-Morning Market Update: Markets Rise; Halliburton Posts Q1 Profit

    Benzinga | Apr. 21, 2014 | 10:27AM EST
  28. Morning Market Movers

    Benzinga | Apr. 21, 2014 | 09:47AM EST
  29. Stock Futures Defend Thin Gains; Halliburton And Revlon Climb

    IBD | Apr. 21, 2014 | 08:58AM EST
  30. Benzinga's Top #PreMarket Gainers

    Benzinga | Apr. 21, 2014 | 08:08AM EST
  31. Barron's Recap: Sunny Skies For Home Depot

    Benzinga | Apr. 20, 2014 | 10:44AM EST
  32. Prosensa Muscular Dystrophy Data Send Stock Rising

    IBD | Mar. 18, 2014 | 12:50PM EST
  33. Benzinga's Top #PreMarket Losers

    Benzinga | Feb. 27, 2014 | 08:12AM EST
  34. UPDATE: Sarepta Announces Positive Safety Results from Phase I Trial of Marburg Drug Candidate

    Benzinga | Feb. 10, 2014 | 08:36AM EST
  35. UPDATE: JMP Downgrades Sarepta, Data Considered Weak and Overstated

    Benzinga | Jan. 27, 2014 | 11:47AM EST
  36. Needham Upgrades Sarepta, Says Stock Underalued Even In Conservative Case

    Benzinga | Jan. 21, 2014 | 12:09PM EST
  37. Is The Market On Drugs?

    Benzinga | Jan. 16, 2014 | 14:30PM EST
  38. Mid-Morning Market Update: Markets Mostly Lower; Goldman Sachs Posts Upbeat Profit

    Benzinga | Jan. 16, 2014 | 10:40AM EST
  39. Morning Market Movers

    Benzinga | Jan. 16, 2014 | 10:02AM EST
  40. Benzinga's Top #PreMarket Gainers

    Benzinga | Jan. 16, 2014 | 08:13AM EST
  41. UPDATE: Sarepta Downgraded by Citigroup on Eteplirsen Early Approval Setback

    Benzinga | Jan. 6, 2014 | 11:25AM EST
  42. Mid-Morning Market Update: Markets Mostly Lower; GE To Acquire Thermo Fisher Assets For $1.06B

    Benzinga | Jan. 6, 2014 | 10:28AM EST
  43. Morning Market Losers

    Benzinga | Jan. 6, 2014 | 10:02AM EST
  44. Benzinga's Top #PreMarket Losers

    Benzinga | Jan. 6, 2014 | 08:19AM EST
  45. UPDATE: Canaccord Genuity Downgrades Sarepta Therapeutics as FDA Talks Continue

    Benzinga | Dec. 6, 2013 | 10:56AM EST
  46. Market Wrap For November 26: Nasdaq Closes Above 4,000 For First Time Since 2000

    Benzinga | Nov. 26, 2013 | 16:44PM EST
  47. Mid-Afternoon Market Update: Markets Rise as NASDAQ Eyes Close Over 4,000

    Benzinga | Nov. 26, 2013 | 15:56PM EST
  48. UPDATE: Deutsche Bank Downgrades Sarepta Therapeutics Following FDA Announcement That NDA Filing is Premature

    Benzinga | Nov. 13, 2013 | 10:17AM EST
  49. Sarepta Plunges And Love Affair Ends (For Now)

    YCharts | Nov. 12, 2013 | 21:18PM EST
  50. Sarepta sinks on FDA report

    IBD | Nov. 12, 2013 | 18:55PM EST
Trading Center